Categories
Blog

Understanding MoCRA and Safety Substantiation Requirements for Cosmetics

The Modernization of Cosmetics Regulation Act (MoCRA) brings significant changes for everyone in the cosmetics industry, from manufacturers to distributors. Its main goal is to make sure that cosmetic products are safe and comply with regulations before they reach consumers.
The main objective of MoCRA was to improve the safety and transparency of cosmetic products. It sets stricter rules for businesses, requiring them to prove their products are safe before they can be sold.
If you’re in the cosmetics business, it’s crucial to understand and follow these new regulations to stay in the market and keep consumers’ trust. Click here if you want to comply with the updated MoCRA cosmetic regulations by FDA. Let’s break down the key parts of MoCRA and the guidelines for proving product safety, so you can easily meet these new requirements.
What is MoCRA?
MoCRA, or the Modernization of Cosmetics Regulation Act, is designed to update and improve the regulatory framework for cosmetics in the U.S. It mandates that cosmetic manufacturers ensure their products are safe for use, substantiated through rigorous testing and documentation. This act aligns the U.S. more closely with international standards, aiming to protect consumers and ensure product safety.
Benefits of MoCRA for businesses
  • Future-Proofs Your Business: MoCRA sets the new standard for cosmetic safety. By complying now, you avoid scrambling to catch up later and ensure your products can stay on shelves.
  • Builds Brand Trust & Loyalty: Consumers are increasingly concerned about safety.
    • MoCRA compliance demonstrates your commitment to safe ingredients and high-quality products, fostering trust and loyalty from customers.
  • Reduces Risk & Saves Money: Recalls, lawsuits and bad publicity due to safety concerns can be financially devastating.
    • MoCRA compliance minimizes these risks, saving you money and protecting your brand reputation.
  • Competitive Advantage: As consumers become more aware of MOCRA, businesses that can clearly communicate their compliance will gain a competitive edge.
Key requirements of MoCRA
  1. Product Registration: As a cosmetic manufacturer, you must register your facilities and products with the FDA under MoCRA . This registration includes detailed information about the ingredients and formulations used in each product. Click to learn about the registration and listing of cosmetic product facilities and products.
  2. Adverse Event Reporting: If your products cause any serious health issues or reactions, you need to report these events to the FDA. This proactive approach helps the FDA monitor product safety and take necessary actions, showing consumers that their well-being is their priority.
  3. Labeling Requirements: MoCRA enforces strict labeling requirements, ensuring that all cosmetic products have accurate and clear ingredient lists. This helps consumers make informed decisions and avoids misleading claims, fostering trust and transparency. Learn here what is MoCRA label compliance.
  4. Good Manufacturing Practices (GMP): According to the act, you must adhere to Good Manufacturing Practices. This means making cosmetics in a clean, controlled, and consistent environment.
    • By sticking to these practices, you reduce the chance of contamination, making your products safer for customers.
    • Consistent manufacturing ensures that every product meets high standards, showing your commitment to quality.
    • Following GMP shows that you care about providing safe and reliable products, and building trust and loyalty with your customers.
Safety Substantiation Guidelines
Safety substantiation is a crucial aspect of MOCRA, requiring you to provide evidence that your products are safe for use. Here are the key steps, explained simply:
1. Assess Ingredient Safety:
  • Scientific Literature Review: Search for published studies on individual ingredients and their safety profiles. Look for reputable sources like peer-reviewed journals and safety data sheets (SDS) provided by suppliers.
  • Testing Options: Consider various testing methods beyond traditional animal testing, which MoCRA doesn’t mandate. Explore alternative methods like:
    • In Vitro (cell-based) testing: Evaluate ingredient effects on cultured cells.
    • Human Volunteer Patch Testing: Assess potential skin irritation or allergic reactions on a small group of volunteers under controlled conditions.
    • Computer Modeling: Utilize computer simulations to predict ingredient behavior and potential risks.
  • Concentration Matters: Evaluate safety based on the specific concentration of each ingredient in the final product. Lower concentrations may pose less risk.
2. Test the Product:
  • Stability Testing: Conduct studies to ensure the product maintains its physical and chemical properties over its shelf life. This includes factors like:
    • Separation
    • Color changes
    • Potential degradation of ingredients.
  • Microbial Testing: Test for potential contamination by bacteria, fungi, or other microorganisms. Implement good manufacturing practices (GMPs) to minimize contamination risk.
  • Clinical Testing: While not always mandatory, consider human volunteer studies to assess the product’s safety and potential for irritation or allergic reactions. Patch tests are a common option for this.
3. Document Everything:
  • Maintain Detailed Records: Create a comprehensive safety substantiation dossier for each cosmetic product. This should include:
    • Ingredient lists with CAS numbers (unique identifiers) and sources.
    • Scientific literature review summaries.
    • Testing protocols and results for all conducted tests.
    • Risk assessments and mitigation strategies.
  • Accessibility for Review: Ensure all documentation is readily available for inspection by the FDA upon request. This demonstrates your commitment to transparent safety practices.
4. Perform Risk Assessments:
  • Hazard Identification: Identify all potential hazards associated with the product, including:
    • Individual ingredient risks.
    • Potential for allergic reactions or skin irritation.
    • Microbiological contamination risks.
    • Improper use or misuse of the product.
  • Evaluate Likelihood and Severity: Assess the probability of each hazard occurring and the potential severity of any adverse effects.
  • Risk Mitigation Strategies: Implement measures to minimize identified risks. This may involve adjusting ingredient concentrations, adding preservatives, or including clear warnings and usage instructions on the label.
Additional Tips:
  • Stay Updated: Keep abreast of evolving scientific data and regulations regarding cosmetic safety.
  • Seek Expert Advice: Consider consulting with cosmetic scientists or regulatory specialists to ensure your safety substantiation practices are robust and compliant.
  • Transparency is Key: Clearly communicate safety information to consumers through product labels and readily accessible safety data sheets.
By following these detailed guidelines, businesses can ensure they meet MoCRA requirements and demonstrate their commitment to providing safe and effective cosmetic products.
Bottom Line
Complying with MoCRA not only ensures regulatory adherence but also enhances consumer trust and product credibility. By demonstrating a commitment to safety and transparency, you can build a loyal customer base and minimize the risk of legal and reputational issues.
Are MoCRA and Safety Substantiation Requirements complex for your cosmetic business? Do not worry !
Categories
Blog

Health Canada’s Regulatory Plan 2024-26: Proposed Amendments to NHP and Non-Prescription Drugs

Health Canada has unveiled its Forward Regulatory Plan for 2024-2026, outlining significant amendments to the Natural Health Products Regulations and the Food and Drug Regulations under the Food and Drugs Act.  

These amendments are designed to align the regulatory approach for self-care products, ensuring a streamlined and risk-based framework that reflects contemporary standards. 

To better understand the proposed amendment, it’s essential to first understand Natural Health Products (NHPs) and Non-Prescription Drugs. 

What is NHP? 

Natural Health Products (NHPs) are a category of health products regulated by Health Canada. These products include a variety of items that support health and wellness through natural means. The category of health products include: 

  • Essential nutrients that support overall health and wellness. 
  • Herbal remedies or plant-based products used for their medicinal properties. 
  • Products based on homeopathy, a system of alternative medicine. 
  • Medicines used traditionally, such as those from traditional Chinese medicine or Ayurvedic medicine. 

Click to learn how you can get an NHP Licence for Nicotine Pouches in Canada? 

What is non-prescription drug? 

Non-Prescription Drugs are medications that can be purchased without a prescription from a healthcare professional. These drugs are also known as Over-the-Counter Drugs or OTC drugs. These drugs are made to treat common, self-diagnosed conditions and symptoms such as pain, fever, coughs, colds, and allergies.  

Examples of OTC drugs are Pain Relievers and Fever Reducers, Cough and Cold Remedies, Allergy Medications and Antacids and Acid Reducers.  

Click this link to learn more about non-prescription drugs, how you can sell it in Canada, and more facts about it.  

Now, let’s explore Health Canada’s Forward Regulatory Plan 2024-26 and outline significant amendments to the Natural Health Products Regulations and the Food and Drug Regulations under the Food and Drugs Act.    

Health Canada forward regulatory plan: key changes proposed 
  1. Simplified Pathways and Alignment:

Health Canada proposes a new system to fast-track approval for lower-risk non-prescription drugs. This system will align these OTC drugs with natural health products that have similar uses. The goal is to streamline the process while still ensuring that safety standards remain high. 

  1. Modernization of Natural Health Products Regulations:

The amendments also target the Natural Health Products Regulations, introducing a structured risk-based categorization system and enhanced quality oversight measures. 

Key proposals include: 
  • Annual Notification Requirement: Businesses will be required to annually notify Health Canada of marketed natural health products, enhancing transparency and regulatory oversight. 
  • Good Manufacturing Practices (GMP): Strengthening requirements for GMP will ensure that natural health products meet high standards of quality throughout the manufacturing process. 
  • Risk-Based Site Licensing: Introducing a risk-based site licensing program will enhance oversight of production facilities, further safeguarding product quality and consistency. 

These amendments are in response to recommendations from the Commissioner of the Environment and Sustainable Development’s 2021 audit, underscoring Health Canada’s commitment to addressing regulatory gaps and enhancing consumer confidence in natural health products. 

International alignment and impact 

While these changes aren’t part of a formal international cooperation plan, they will bring Canada’s regulations closer to those of the U.S., EU, and Australia. This alignment should make it easier for Canadian businesses to compete globally and ensure imported products meet Canadian standards. 

What it means for businesses and consumers 

The proposed amendments are expected to impact businesses involved in the sale and manufacture of natural health products and non-prescription drugs in Canada.  

  • For natural health products, the amendments promise strengthened oversight and improved assurance of product quality, aligning with global best practices.  
  • Meanwhile, amendments to the Food and Drug Regulations aim to maintain robust regulatory oversight while reducing administrative burdens and enhancing operational efficiencies for businesses. 
Consultations and stakeholder engagement 

Health Canada has engaged stakeholders extensively since 2016 and will continue to do so throughout 2024. The recent publication of regulatory amendments in the Canada Gazette, Part II on July 6, 2022, marked a significant milestone in this ongoing consultation process. These consultations are crucial for gathering feedback from industry stakeholders, healthcare professionals, and the public to ensure that the regulatory framework remains responsive and effective. 

Get assisted by Quality Smart Solutions 

For detailed insights into these regulatory changes and ongoing consultations, reach out to our team of former Health Canada experts at Quality Smart Solutions. We help ensure compliance with modernized regulations governing natural health products (NHPs) and non-prescription drugs, enhancing safety and quality standards across Canada while facilitating business growth and innovation.   

  

Categories
Blog

Health Canada 2024 Drug Establishment Licensing (DEL) Update

Health Canada is introducing a new plan to modernize the Drug Establishment Licensing (DEL) framework over the coming years. This plan, divided into two phases, focuses on strengthening regulatory oversight, aligning with international standards, and easing administrative burdens. 

Before going into details of the update, let’s throw light on what DEL is and who needs it. 

What is Drug Establishment Licensing (DEL)?  

Health Canada’s Drug Establishment Licensing (DEL) is a regulatory framework that governs the licensing of establishments involved in the drug manufacturing and distribution process in Canada. The DEL program is designed to ensure that drugs and related products meet high standards of quality, safety, and efficacy before they are available on the Canadian market. 

Click here to learn more about DEL. 

Who Needs DEL?  

  • Manufacturers: Facilities that produce, package, or label drugs must obtain a DEL to ensure compliance with Good Manufacturing Practices (GMP). 
  • Distributors: Establishments involved in the import, export, and distribution of drugs also require a DEL. 
  • Importers/Exporters: Entities involved in importing or exporting drugs must hold a DEL to ensure adherence to regulatory requirements. 

Want to know why Drug Establishment Registration (DEL) is important for you? Read this blog 

2024 DEL Updates 

Here’s a breakdown of what DEL updates in 2024 by Health Canada mean and how they will impact your businesses and consultants involved in drug establishment licensing in Canada. 

What is the Drug Establishment Licensing Framework? 

The DEL framework governs the licensing of businesses that manufacture, package, label, import, distribute, and wholesale drugs in Canada. This framework ensures that drugs available to Canadians are safe, effective, and of high quality. 

Phase 1: Enhancing Drug Recall and Testing Regulations 

The first phase of Health Canada’s plan includes several important updates: 

  1. New Drug Recall Framework: A structured regulatory framework will be established for recalls ordered by the Minister of Health. This will streamline the recall process, ensuring faster and more efficient action to protect public health. 
  1. Clear Reporting for Voluntary Recalls: Businesses will have clear guidelines on their obligations for reporting voluntary recalls, aligning with current policies to improve transparency and accountability. 
  1. Updated Mutual Recognition Agreements (MRAs): Outdated references to regulatory authorities in mutual recognition agreements will be replaced with a dynamic list accessible on the Government of Canada website. This makes it easier for businesses to stay up-to-date with recognized authorities. 
  1. Testing Exemptions for Advanced Therapies: Conditional exemptions will be introduced for certain biologics (like gene and cell therapies) and radiopharmaceuticals from some finished product testing requirements. This will apply where alternative safety controls are in place, supporting the development and accessibility of these advanced treatments. 
  1. Direct Shipment Provisions: Clarification that certain biologics and radiopharmaceuticals can be directly shipped to healthcare practitioners or facilities. This helps ensure timely access to critical treatments. 
Phase 2: Streamlining Licensing and Compliance 

The second phase will focus on reducing the regulatory burden and modernizing compliance measures: 

  1. Simplified Annual Licence Review: The annual review process for establishment licences will be simplified, reducing the administrative workload for businesses and Health Canada. 
  1. Modern Compliance Tools: Provisions related to compliance and enforcement will be updated, including the use of terms and conditions and suspensions. This will provide a more flexible and effective regulatory framework. 
  1. Flexible Oversight: Less prescriptive regulations will be introduced, maintaining appropriate oversight while allowing more flexibility in regulated activities. This approach aligns with a risk-based regulatory philosophy, focusing resources where they are most needed. 
Benefits 2024 DEL Updates for Businesses and Consultants 

Enhanced Efficiency: The updated recall framework and clear reporting obligations will help businesses manage recalls more efficiently, minimizing disruptions and protecting their reputations. 

Simplified Compliance: By updating MRAs and introducing conditional exemptions, Health Canada is making it easier for businesses to navigate regulatory requirements, particularly for advanced therapies. 

You should know that MRAs are formal agreements between countries or regions to accept each other’s regulatory evaluations and certifications for certain products, services, or processes. 

Reduced Administrative Burden: The streamlined annual licence review and modern compliance tools will significantly reduce the time and effort businesses need to spend on regulatory processes. 

International Alignment: Aligning Canada’s regulations with those of major international partners like the U.S., EU, UK, Australia, and Switzerland will facilitate smoother trade and regulatory processes, benefiting Canadian businesses operating globally. 

What’s Next? 

Health Canada has been actively engaging with stakeholders throughout this process: 

  • Initial Consultations: Between April and June 2019, Health Canada consulted with DEL and Medical Device Establishment Licensing (MDEL) holders. 
  • Notice of Intent: In December 2021, a notice of intent was published in the Canada Gazette, Part I, followed by a 60-day comment period. 
  • Public Comments: Proposed changes for Phase 1 were pre-published in the Canada Gazette, Part I on April 15, 2023. During the 75-day comment period, Health Canada received feedback from 46 respondents, including individuals, businesses, and associations. 
Publication Timeline: 
  • The final regulations for Phase 1 are expected to be published in the Canada Gazette, Part II in spring 2024. 
  • Proposed amendments for Phase 2 will be pre-published in the Canada Gazette, Part I in winter/spring 2025, followed by another 75-day comment period. 

By modernizing the DEL framework, Health Canada aims to enhance drug safety, streamline regulatory processes, and support the growth of the pharmaceutical industry in Canada 

Businesses and consultants should prepare for these changes, which promise to bring greater clarity, efficiency, and international alignment to the regulatory landscape. 

How Quality Smart Solutions can help you 

At Quality Smart Solutions, we’re dedicated to helping you stay ahead of regulatory changes. Our team of experts is ready to guide you through the new DEL framework, ensuring your drug establishment practices meet the latest standards. Contact us today to learn how we can support your regulatory needs! 

Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.